Bar-Eli M
Department of Cancer Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.
Pigment Cell Res. 2001 Apr;14(2):78-85. doi: 10.1034/j.1600-0749.2001.140202.x.
The molecular changes associated with the transition of melanoma cells from radial growth phase (RGP) to vertical growth phase [(VGP), metastatic phenotype] are not very well defined. We previously demonstrated that expression of the cell-surface adhesion molecule MCAM/MUC18 correlates directly with the metastatic potential of human melanoma cells. In addition, the progression of human melanoma towards the metastatic phenotype is associated with loss of expression of the tyrosine-kinase receptor c-KIT. In this review, I will summarize our recent studies demonstrating that the expression of both genes is regulated by the AP-2 transcription factor. Moreover, we have observed a loss of AP-2 expression in metastatic melanoma cells. Re-expression of AP-2 in the highly metastatic A375SM cells decreased their tumorigenicity and inhibited their metastatic potential in nude mice. MCAM/MUC18 mRNA and protein expression was significantly down-regulated while c-KIT expression was up-regulated in the AP-2-transfected cells. To further investigate the role of AP-2 in the progression of human melanoma, we attempted to inactivate AP-2 in primary cutaneous melanoma by using a dominant-negative AP-2, or the AP-2B gene. Expression of AP-2B in SB-2 cells augmented their tumorigenicity in nude mice, and upregulated MMP-2 expression and activity. As AP-2 also regulates other genes that are involved in the progression of human melanoma such as E-cadherin, p21/WAF-1, HER2/neu, Bcl-2, FAS/APO-1, IGF-R-1, VEGF and the thrombin receptor (PAR-1), we therefore propose that loss of AP-2 is a crucial event in the development of malignant melanoma. In addition, the transition of melanoma cells from RGP to VGP is also associated with over-expression of the transcription factors CREB and ATF-1. The notion that the balance between AP-2 and CREB/ATF-1 expression determines the progression of melanoma cells towards the metastatic phenotype will be discussed.
与黑色素瘤细胞从径向生长期(RGP)转变为垂直生长期[(VGP),转移表型]相关的分子变化尚未完全明确。我们之前证明,细胞表面黏附分子MCAM/MUC18的表达与人类黑色素瘤细胞的转移潜能直接相关。此外,人类黑色素瘤向转移表型的进展与酪氨酸激酶受体c-KIT表达的缺失有关。在这篇综述中,我将总结我们最近的研究,这些研究表明这两个基因的表达均受AP-2转录因子调控。此外,我们观察到转移性黑色素瘤细胞中AP-2表达缺失。在高转移性A375SM细胞中重新表达AP-2降低了它们的致瘤性,并抑制了它们在裸鼠中的转移潜能。在AP-2转染的细胞中,MCAM/MUC18的mRNA和蛋白表达显著下调,而c-KIT表达上调。为了进一步研究AP-2在人类黑色素瘤进展中的作用,我们试图通过使用显性负性AP-2或AP-2B基因使原发性皮肤黑色素瘤中的AP-2失活。AP-2B在SB-2细胞中的表达增强了它们在裸鼠中的致瘤性,并上调了MMP-2的表达和活性。由于AP-2还调控其他参与人类黑色素瘤进展的基因,如E-钙黏蛋白、p21/WAF-1、HER2/neu、Bcl-2、FAS/APO-1、IGF-R-1、VEGF和凝血酶受体(PAR-1),因此我们提出AP-2的缺失是恶性黑色素瘤发生发展中的一个关键事件。此外,黑色素瘤细胞从RGP向VGP的转变还与转录因子CREB和ATF-1的过表达有关。将讨论AP-2与CREB/ATF-1表达之间的平衡决定黑色素瘤细胞向转移表型进展这一观点。